Skip to main content
SpringerLink
Log in
Book cover

Hepatology Principles and Practice pp 263–285Cite as

Hepatic encephalopathy

  • Chapter

  • 1548 Accesses

Keywords

  • Hepatic Encephalopathy
  • Cirrhotic Patient
  • Acute Liver Failure
  • Visually Evoke Potential
  • Urea Cycle

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amodio, P., del Piccolo, F., Marchetti, P., Angeli, P., Iemmolo, R., Caregaro, L., Merkel, C., Gerunda, G., Gatta, A.: Clinical features and survival of cirrhotic patients with subclinical cognitive alterations by the number connection test and computerized psychometric tests. Hepatology 1999; 29: 1662–1667

    CrossRef  CAS  PubMed  Google Scholar 

  2. Amodio, P., del Piccolo, F., Petteno, E., Mapelli, D., Angeli, P., Iemmolo, R. Muraca, M., Musto, C., Gerunda, G., Rizzo, C., Merkel, C., Gatta, A.: Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J. Hepatol. 2001; 35: 37–45

    CrossRef  CAS  PubMed  Google Scholar 

  3. Arora, A., Seth, S., Acharya, S.K., Sharma, M.P.: Hepatic coma as a presenting feature of constrictive pericarditis. Amer. J. Gastroenterol. 1993; 88: 430–432

    CAS  Google Scholar 

  4. Barsotti, R.J.: Measurement of ammonia in blood. J. Pediatr. 2001; 138(Suppl.): 11–19

    Google Scholar 

  5. Basile, A.S., Jones, E.A., Skolnick, P.: The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol. Rev. 1991; 43: 27–71

    CAS  PubMed  Google Scholar 

  6. Basile, A.S., Jones, E.A.: Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25: 1303–1305

    CrossRef  CAS  PubMed  Google Scholar 

  7. Belay, E.D., Bresee, J.S., Holman, R.C., Khan, A.S., Shahriari, A., Schonberger, L.-B.: Reye’s syndrome in the United States from 1981 through 1987. New Engl. J. Med. 1999; 340: 1377–1382

    CrossRef  CAS  PubMed  Google Scholar 

  8. Bernardini, P., Fischer, J.E.: Amino acid imbalance and hepatic encephalopathy. Ann. Rev. Nutr. 1982; 2: 419–454

    CAS  Google Scholar 

  9. Bessman, A.N., Mirik, G.S., Hawkins, R.: Blood ammonia levels following the ingestion of casein and whole blood. J. Clin. Invest. 1958; 37: 990–998

    CAS  PubMed  Google Scholar 

  10. Blom, H.J., Ferenci, P., Grimm, G., Yap, S.H., Tangerman, A.: The role of methanethiol in the pathogenesis of hepatic encephalopathy. Hepatology 1991; 13: 445–454

    CrossRef  CAS  PubMed  Google Scholar 

  11. Bosman, D.K., Deutz, N.E.P., Graaf, de, A.A., Hulst, van der, R.W.N., Eijk, van, H.M.H., Boveé, W.M.M.J., Maas, M.A.W., Jörning, G.G.A., Chamuleau, R.A.F.M.: Changes in brain metabolism during hyperammonemia and acute liver failure: results of a comparative “H-NMR spectroscopy and biochemical investigation. Hepatology 1990; 12: 281–290

    CAS  PubMed  Google Scholar 

  12. Brown, J.K., Imam, H.: Interrelationships of liver and brain with special reference to Reye syndrome. J. Inher. Metabol. Dis. 1991; 14: 436–458

    CAS  Google Scholar 

  13. Bullimore, D.: The role of polyamines in hepatic encephalopathy and cerebral oedema. Europ. J. Gastroenterol. Hepatol. 1993; 5: 63–67

    Google Scholar 

  14. Bustamante, J., Rimola, A., Ventura, P.J., Navasa, M., Cirera, I., Reggiardo, V., Rodes, J.: Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J. Hepatol. 1999; 30: 890–895

    CrossRef  CAS  PubMed  Google Scholar 

  15. Butterworth, R.F.: The neurobiology of hepatic encephalopathy. Semin. Liver Dis. 1996; 16: 235–244

    CAS  PubMed  Google Scholar 

  16. Cabré, E., Periago, J.L., Gonzalez, J., Gonzalez-Huix, F., Abad-Lacruz, A., Gil, A., Sanchez-Medina, F., Esteve-Comas, M., Fernandez-Banares, F., Planas, R., Gassull, M.A.: Plasma polyunsaturated fatty acids in liver cirrhosis with or without chronic hepatic encephalopathy: a preliminary study. J. Parenter. Enter. Nutr. 1992; 16: 359–363

    Google Scholar 

  17. Cadranel, J.-F., Lebiez, E., di Martino, V., Bernard, B., El Koury, S., Tourbah, A., Pidoux, B., Valla, D., Opolon, P.: Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity? Amer. J. Gastroenterol. 2001; 96: 515–518

    CAS  Google Scholar 

  18. Calvet, X., Nogueras, C., Roque, M., Sanfeliu, I.: Helicobacter pylori is not a risk factor for hepatic encephalopathy. Dig. Liver Dis. 2001; 33: 414–419

    CrossRef  CAS  PubMed  Google Scholar 

  19. Campollo, O., MacGillivray, B., McIntyre, N.: Asociacion entre los niveles de amonio y GABA plasmaticos y el grado de encefalopatia hepatica. Rev. Invest. Clin. 1992; 44: 483–490

    CAS  PubMed  Google Scholar 

  20. Chang, K.J., Hoefs, J.C.: Ascites and encephalopathy. Curr. Opin. Gastroenterol. 1992; 8: 398–402

    Google Scholar 

  21. Cordoba, J., Blei, A.T.: Brain edema and hepatic encephalopathy. Semin. Liver Dis. 1996; 16: 271–280

    CAS  PubMed  Google Scholar 

  22. Das, A., Dhiman, R.K., Saraswat, V.A., Verma, M., Naik, S.R.: Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J. Gastroenterol. Hepatol. 2001; 16: 531–535

    CrossRef  CAS  PubMed  Google Scholar 

  23. Davidson, E.A., Summerskill, W.H.J.: Psychiatric aspects of liver disease. Postgrad. Med. J. 1956; 32: 487–494

    CAS  PubMed  Google Scholar 

  24. Dietrich, R., Bachmann, C., Lauterburg, B.H.: Exercise-induced hyperammonemia in patients with compensated chronic liver disease. Scand. J. Gastroenterol. 1990; 25: 329–334

    CAS  PubMed  Google Scholar 

  25. Ferenci, P., Püspök, A., Steindl, P.: Current concepts in the pathophysiology of hepatic encephalopathy. Eur. J. Clin. Invest. 1992; 22: 573–581

    CAS  PubMed  Google Scholar 

  26. Fischer, J.E., Baldessarini, R.J.: False neurotransmitters and hepatic failure. Lancet 1971/II: 75–80

    Google Scholar 

  27. Flannery, D.B., Hsia, Y.E., Wolf, B.: Current status of hyperammonemic syndromes. Hepatology 1982; 2: 495–506

    CAS  PubMed  Google Scholar 

  28. Geissler, A., Lock, G., Fründ, R., Held, P., Hollerbach, S., Andus, T., Schölmerich, J., Feuerbach, S., Holstege, A.: Cerebral abnormalities in patients with cirrhosis detected by proton magnetic resonance spectroscopy and magnetic resonance imaging. Hepatology 1997; 25: 48–54

    CAS  PubMed  Google Scholar 

  29. Gitlin, N., Lewis, D.C., Hinkley, L.: The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J. Hepatol. 1986; 3: 75–82

    CrossRef  CAS  PubMed  Google Scholar 

  30. Goldstein, G.W.: The role of brain capillaries in the pathogenesis of hepatic encephalopathy. Hepatology 1984; 4: 565–567

    CAS  PubMed  Google Scholar 

  31. Grippon, P., Le Poncin-Lafitte, M., Boschat, M., Wang, S., Faure, G., Dutertre, D., Opolon, P.: Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan. Hepatology 1986; 6: 682–686

    PubMed  Google Scholar 

  32. Groeneweg, M., Moerland, W., Quero, J.C., Hop, W.C.J., Krabbe, P.F., Schalm, S.W.: Screening of subclinical hepatic encephalopathy. J. Hepatol. 2000; 32: 748–753

    CrossRef  CAS  PubMed  Google Scholar 

  33. Grüngreiff, K., Wolf, G., Schmidt, W., Franke, D., Kleine, F.-D.: Highaffinity uptake of transmitter glutamate (GLU)in brain tissue with reference to hepatic encephalopathy (HE). Z. Gastroenterol. 1991; 29(Suppl. 2): 95–100

    Google Scholar 

  34. Grüngreiff, K.: Zinc in liver disease. J. Trace Elem. Exp. Med. 2002; 15: 67–78

    Google Scholar 

  35. Güven, K., Kelestimur, F., Yücesoy, M.: Thyroid function tests in nonalcoholic cirrhotic patients with hepatic encephalopathy. Eur. J. Med. 1993; 2: 83–85

    PubMed  Google Scholar 

  36. Hashimoto, N., Ashida, H., Kotoura, Y., Nishioka, A., Nishiwaki, M., Utsunomiya, J.: Analysis of hepatic encephalopathy after distal splenorenal shunt-PTP image and pancreatic hormone kinetics. Hepato-Gastroenterol. 1993; 40: 360–364

    CAS  Google Scholar 

  37. Häussinger, D., Steeb, R., Gerok, W.: Metabolic alkalosis as driving force for urea synthesis in liver disease: pathogenetic model and therapeutic implications. Clin. Invest. 1992; 70: 411–415

    Google Scholar 

  38. Häussinger, D., Laubenberger, J., von Dahl, S., Ernst, T., Langer, H., Gerok, W., Hennig, J.: Proton magnetic resonance studies on human brain myo-inositol during hypoosmolarity and hepatic encephalopathy. Gastroenterology 1994; 107: 1475–1480

    PubMed  Google Scholar 

  39. Hartmann, I.J.C., Groeneweg, M., Quero, J.C., Beijeman, S.J., de Man, R.A., Hop, W.C.J., Schalm, S.W.: The prognostic significance of subclinical hepatic encephalopathy. Amer. J. Gastroenterol. 2000; 95: 2029–2034

    CAS  Google Scholar 

  40. Held, C., Rühle, R., Steppuhn, S., Wack, R.: Fahrtauglichkeit bei Patienten mit hepatischer Enzephalopathie nach portosystemischer Shunt-Operation. Z. Gastroenterol. (Suppl. 2) 1991; 29: 107–109

    Google Scholar 

  41. Höckerstedt, K., Kajaste, S., Muuronen, A., Raininko, R., Seppäläinen, A.-M., Hillbom, M.: Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation. J. Hepatol. 1992; 16: 31–37

    PubMed  Google Scholar 

  42. Homann, J., Kuntz, H.-D., Deetjen, W., Thilo-Körner, D.S., Oehler, G.: Die chronische hepatische Enzephalopathie. Med. Welt 1993; 44: 128–134

    Google Scholar 

  43. Huber, M., Rössle, M., Siegerstetter, V., Ochs, A., Haag, K., Kist, M., Blum, H.E.: Helicobacter pylori infection does not correlate with plasma ammonia concentration and hepatic encephalopathy in patients with cirrhosis. Hepato-Gastroenterol. 2001; 48: 541–544

    CAS  Google Scholar 

  44. Jalan, R., Seery, J.P., Taylor-Robinson, S.D.: Review article: pathogenesis and treatment of chronic hepatic encephalopathy. Aliment. Pharmacol. Ther. 1996; 10: 681–697

    CrossRef  CAS  PubMed  Google Scholar 

  45. James, J.H., Ziparo, V., Jeppson, B., Fischer, J.E.: Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy. Lancet 1979/II: 772–775

    Google Scholar 

  46. Jessy, J., Mans, A.M., DeJoseph, M.R., Hawkins, R.A.: Hyperammonaemia causes many of the changes found after portocaval shunting. Biochem. J. 1990; 272: 311–317

    CAS  PubMed  Google Scholar 

  47. Jessy, J., DeJoseph, M.R., Hawkins, R.A.: Hyperammonaemia depresses glucose consumption throughout the brain. Biochem. J. 1991; 277: 693–696

    CAS  PubMed  Google Scholar 

  48. Joelsson, B., Aslund, U., Hultberg, B., Alwmark, A., Gullstrand, P., Bengmark, S.: Portal-systemic encephalopathy. Influence of shunt surgery and relations to serum amino acids. Scand. J. Gastroenterol. 1986; 21:900–906

    CAS  PubMed  Google Scholar 

  49. Jones, D.B.: Hepatic encephalopathy. J. Gastroenterol. Hepatol. 1993; 8: 363–369

    CAS  PubMed  Google Scholar 

  50. Kardel, T., Lund, Y., Zander Olsen, P., Möllgaard, V., Gammeltoft, A.: Encephalopathy and portacaval anastomosis. Scand. J. Gastroenterol. 1970; 5: 681–685

    CAS  PubMed  Google Scholar 

  51. Kerlan, R.K. jr., Sollenberger, R.D., Palubinskas, A.J., Raskin, N.H., Callen, P.W., Ehrenfeld, W.K.: Portal-systemic encephalopathy due to a congenital portocaval shunt. Amer. J. Roentgenol. 1982; 139: 1013–1015

    Google Scholar 

  52. Kircheis, G., Wettstein, M., Timmermann, L., Schnitzler, A., Häussinger, D.: Critical flicker frequency for quantification of low-grad hepatic encephalopathy. Hepatology 2002; 35: 357–366

    CrossRef  PubMed  Google Scholar 

  53. Knudsen, G.M., Schmidt, J., Almdal, T., Paulson, O.B., Vilstrup, H.: Passage of amino acids and glucose across the blood-brain barrier in patients with hepatic encephalopathy. Hepatology 1993; 17: 987–992

    CrossRef  CAS  PubMed  Google Scholar 

  54. Kramer, L., Tribl, B., Gendo, A., Zauner, C., Schneider, P., Ferenci, P., Madl, C.: Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000; 31: 30–34

    CrossRef  CAS  PubMed  Google Scholar 

  55. Kreis, R., Ross, B.D., Farrow, N.A.: Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992; 182: 19–27

    CAS  PubMed  Google Scholar 

  56. Krieger, D., Krieger, S., Jansen, O., Gass, P., Theilmann, L., Lichtnecker, H.: Manganese and chronic hepatic encephalopathy. Lancet 1995; 346: 270–274

    CrossRef  CAS  PubMed  Google Scholar 

  57. Kuntz, E.: Hepatische Enzephalopathie. Psychometrische Tests zur Diagnose, Bewertung und Therapiekontrolle in der Praxis. Münch. Med. Wschr. 1992; 134: 76–80

    Google Scholar 

  58. Laubenberger, J., Häussinger, D., Bayer, S., Gufler, H., Hennig, J., Langer, M.: Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997; 112: 1610–1616

    CrossRef  CAS  PubMed  Google Scholar 

  59. Levy, L.J., Losowsky, M.S.: Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease. Hepato-Gastroenterol. 1989; 36:494–498

    CAS  Google Scholar 

  60. Löscher, W., Kretz, F.-J., Karavias, T., Dillinger, U.: Marked increases of plasma gamma-aminobutyric acid concentrations in cirrhotic patients with portocaval shunts are not associated with alterations of cerebral functions. Digestion 1991; 49: 212–220

    PubMed  Google Scholar 

  61. Marchesini, G., Zoli, M., Dondi, C., Cecchini, L., Angiolini, A., Bianchi, F.B., Pisi, E.: Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. Dig. Dis. Sci. 1980; 25: 763–768

    CrossRef  CAS  PubMed  Google Scholar 

  62. Mardini, H.A., Harrison, E.J., Ince, P.G., Bartlett, K., Record, C.O.: Brain indoles in human hepatic encephalopathy. Hepatology 1993; 17: 1033–1040

    CrossRef  PubMed  Google Scholar 

  63. Martini, G.A.: Psychiatrisch-neurologische Störungen bei chronischen Leberkrankheiten. Internist 1975; 16: 20–24

    CAS  PubMed  Google Scholar 

  64. Minuk, G.Y.: Gamma-aminobutyric acid and the liver. Dig. Dis. 1993; 11: 45–54

    CAS  PubMed  Google Scholar 

  65. Miquel, J., Barcena, R., Boixeda, D., Fernandez, J., Lopez-San Roman, A., Martin-de-Argila, C., Ramosa, F.: Role of Helicobacter pylori infection and its eradication in patients with subclinical hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 2001; 13: 1067–1072

    CAS  PubMed  Google Scholar 

  66. Mohapatra, M.K., Mohapatra, A.K., Acharya, S.K., Sahni, P., Nundy, S.: Encephalopathy in patients with extrahepatic obstruction after lienorenal shunts. Brit. J. Surg. 1992; 79: 1103–1105

    CAS  PubMed  Google Scholar 

  67. Moore, J.W., Dunk, A.A., Crawford, J.R., Deans, H., Besson, J.A.O., de Lacey, G., Sinclair, T.S., Mowat, N.A.G., Brunt, P.W.: Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently health non-encephalopathic patients with cirrhosis. A controlled study. J. Hepatol. 1989; 9: 319–325

    CAS  Google Scholar 

  68. Mousseau, D.D., Butterworth, R.F.: Current theories on the pathogenesis of hepatic encephalopathy. Proc. Soc. Exper. Biol. Med. 1994; 206: 329–344

    CAS  Google Scholar 

  69. Mullen, K.D., Szauter, K.M., Kaminsky-Russ, K.: “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990; 336: 81–83

    CrossRef  CAS  PubMed  Google Scholar 

  70. Mullen, K.D., Weber, F.L.: Role of nutrition in hepatic encephalopathy. Semin. Liver Dis. 1991; 4: 292–304

    Google Scholar 

  71. Müting, D., Kalk, J.-F., Wuzel, H., Flasshoff, H.J., Bucsis, L.: Störungen des Aminosäurenstoffwechsels bei Leberzirrhose ohne und mit hepatischer Enzephalopathie (HPLC-Untersuchungen an 225 Patienten). Inn. Med. 1986; 13: 137–143

    Google Scholar 

  72. Nolte, W., Wiltfang, J., Schindler, C., Münke, H., Unterberg, K., Zumhasch, U., Figulla, H.R., Werner, G., Hartmann, H., Ramadori, G.: Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 1998; 28: 1215–1225

    CrossRef  CAS  PubMed  Google Scholar 

  73. Norenberg, M.D.: Astrocytic-ammonia interactions in hepatic encephalopathy. Semin. Liver Dis. 1996; 16: 245–253

    CAS  PubMed  Google Scholar 

  74. Odeh, M.: Endotoxin and tumor necrosis factor-? in the pathogenesis of hepatic encephalopathy. J. Clin. Gastroenterol. 1994; 19: 146–153

    CAS  PubMed  Google Scholar 

  75. Ono, J., Hutson, D.G., Dombro, R.S., Levi, J.U., Livingstone, A., Zeppa, R.: Tryptophan and hepatic coma. Gastroenterology 1978; 74: 196–200

    CAS  PubMed  Google Scholar 

  76. Phillips, G.B., Schwartz, R., Gabuzda, G.J., Dabidson, C.S.: The syndrome of impending hepatic coma in patients with cirrhosis of the liver given certain nitrogenous substances. New Engl. J. Med. 1952; 247: 239–246

    CAS  PubMed  Google Scholar 

  77. Planas, R., Gomes-Vieira, M.C., Cabré, E., Armengol, M., Quer, J.C., Boix, J., Morillas, R., Abad-Lacruz, A., Broggi, M., Gassull, M.A.: Prognostic factors of hepatic encephalopathy after portocaval anastomosis: a multivariate analysis in 50 patients. Amer. J. Gastroenterol. 1992; 87: 1792–1796

    CAS  Google Scholar 

  78. Pomier-Layrargues, G., Nooc Huu Nguyen, Faucher, C., Giguére, J.-F., Butterworth, R.F.: Subclinical hepatic encephalopathy in cirrhotic patients: prevalence and relationship to liver function. Canad. J. Gastroenterol. 1991; 5: 121–125

    Google Scholar 

  79. Quero, J.C., Schalm, S.W.: Subclinical hepatic encephalopathy. Semin. Liver Dis. 1996; 16: 321–328

    CAS  PubMed  Google Scholar 

  80. Raskin, N.H., Price, J.B., Fishman, R.A.: Portal-systemic encephalopathy due to congenital intrahepatic shunts. New Engl. J. Med. 1964; 270: 225–229

    CAS  PubMed  Google Scholar 

  81. Rijt, van der, C.C.D., Schalm, S.W., Schat, H., Foeken, K., Jong, de, G.: Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991; 100: 1114–1118

    PubMed  Google Scholar 

  82. Rikkers, L., Jenko, P., Rudman, D., Freides, D.: Subclinical hepatic encephalopathy: detection, prevalence and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462–469

    CAS  PubMed  Google Scholar 

  83. Rink, C., Mantel, E., Haerting, J.: Ambulante Diagnose und Therapiekontrolle der porto-systemischen Enzephalopathie bei Patienten mit Leberzirrhose. Dtsch. Z. Verdau. Stoffwechselkrankh. 1985; 45: 295–301

    CAS  Google Scholar 

  84. Roberts, E.: The-aminobutyric acid (GABA) system and hepatic encephalopathy. Hepatology 1984; 4: 342–345

    CAS  PubMed  Google Scholar 

  85. Romero-Gomez, M., Boza, F., Garcia-Valdecasas, M:S., Garcia, E., Aguilar-Reina, J.: Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Amer. J. Gastroenterol. 2001; 96: 2718–2723

    CAS  Google Scholar 

  86. Romero-Gomez, M., Grande, L., Camacho, I., Benitez, S., Irles, J.A., Castro, M.: Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J. Hepatol. 2002; 37: 781–787

    CAS  PubMed  Google Scholar 

  87. Rose, C., Butterworth, R.F., Zayed, J., Normandin, L., Todd, K., Michalak, A., Spahr, L., Huet, P.M., Pomier Layrargues, G.: Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640–644

    CrossRef  CAS  PubMed  Google Scholar 

  88. Ross, B., Kreis, R., Farrow, N.A., Ackerman, Z.: Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. Radiology 1992; 182: 19–27

    PubMed  Google Scholar 

  89. Rudman, D., Smith III, R.B., Salam, A.A., Warren, W.D., Galambos, J.T., Wenger, J.: Ammonia content of food. Amer. J. Clin. Nutr. 1973; 26: 487–490

    CAS  Google Scholar 

  90. Sanyal, A.J., Freedman, A.M., Shiffman, M.L., Purdum, P.P., Luketic, V.A., Cheatham, A.K.: Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 46–55

    CrossRef  CAS  PubMed  Google Scholar 

  91. Sarin, S.K., Nundy, S.: Subclinical encephalopathy after portosystemic shunts in patients with non-cirrhotic portal fibrosis. Liver 1985; 5: 142–146

    CAS  PubMed  Google Scholar 

  92. Saxena, N., Bhatia, M., Joshi, Y.K., Garg, P.K., Dwivedi, S.N., Tandon, R.K.: Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver 2002; 22: 190–197

    PubMed  Google Scholar 

  93. Schafer, D.F., Jones, E.A.: Hepatic encephalopathy and the γ-aminobutyric acid neurotransmitter system. Lancet 1982/I: 118–20

    Google Scholar 

  94. Schomerus, H., Hamster, W., Blunck, H., Reinhard, U., Mayer, K., Dölle, W.: Latent portosystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig. Dis. Sci. 1981; 26: 622–630

    CrossRef  CAS  PubMed  Google Scholar 

  95. Schomerus, H., Schreiegg, J.: Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice. Z. Gastroenterol. 1993; 31: 231–234

    CAS  PubMed  Google Scholar 

  96. Seery, J.P., Taylor-Robinson, D.: The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. J. Hepatol. 1996; 25: 988–998

    CrossRef  CAS  PubMed  Google Scholar 

  97. Shimamoto, C., Hirata, I., Katsu, K.: Breath and blood ammonia in liver cirrhosis. Hepato-Gastroenterol. 2000; 47: 443–445

    CAS  Google Scholar 

  98. Silva, G., Teres, J., Salmeron, J.M., Masana, J., Visa, J., Pera, C., Rodes, J.: El analisis espectral del electroencefalograma (EEG) predice la aparicion de encefalopatia hepatica en pacientes cirroticos sometidos a anastomosis esplenorrenal distal. Gastroenterol. Hepatol. 1990; 13: 1–5

    Google Scholar 

  99. Silva, G., Segovia, R., Ponce, R., Backhouse, C., Palma, M., Roblero, J.P., Abadal, J., Quijada, C., Troncoso, M., Iturriaga, H.: Effects of 5-isosorbide mononitrate and propranol on subclinical hepatic encephalopathy and renal functions in patients with liver cirrhosis. Hepato-Gastroenterol. 2002; 49: 1357–1362

    CAS  Google Scholar 

  100. Spahr, L., Butterworth, R.F., Fontaine, S., Bui, L., Therrien, G., Milette, P.C., Lebrun, L.H., Zayed, J., Leblanc, A., Pomier-Layrargues, G.: Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996; 24: 1116–1120

    CAS  PubMed  Google Scholar 

  101. Stahl, J.: Studies of the blood ammonia in liver disease. Its diagnostic, prognostic and therapeutic significance. Ann. Intern. Med. 1963; 58: 1–24

    CAS  PubMed  Google Scholar 

  102. Strauss, E., Ferreira da Costa, M.: The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. Hepato-Gastroenterol. 1998; 45: 900–904

    CAS  Google Scholar 

  103. Sudhamshu, K.C., Matsutani, S., Maruyama, H., Fukamachi, T., Nomoto, H., Akiike, T., Ebara, M., Saisho, H.: Portal-systemic encephalopathy in two patients without liver cirrhosis and portal hypertension. Hepatol. Res. 2002; 23: 122–129

    Google Scholar 

  104. Tarter, R.E., Hegedus, A.M., van Thiel, D.H., Schade, R.R., Gavaler, J.S., Starzl, T.E.: Nonalcoholic cirrhosis associated with neuropsychological dysfunction in the absence of overt evidence of hepatic encephalopathy. Gastroenterology 1984; 86: 1421–1427

    CAS  PubMed  Google Scholar 

  105. Tarter, R.E., Switala, J., Plail, J., Havrilla, J., Thiel, van, D.H.: Severity of hepatic encephalopathy before liver transplantation is associated with quality of life after transplantation. Arch. Intern. Med. 1992; 152: 2097–2101

    CrossRef  CAS  PubMed  Google Scholar 

  106. Thirlby, R.C., Fenster, L.F., Coatsworth, J.J., Petty, F.: Reversal of chronic hepatic encephalopathy by colonic exclusion: poor correlation with blood GABA levels. Amer. J. Gastroenterol. 1990; 85: 1637–1641

    CAS  Google Scholar 

  107. Tien, R., Arieff, A.I., Kucharczyk, W., Wasik, A., Kucharczyk, J.: Hyponatremic encephalopathy: is central pontine myelinolysis a component? Amer. J. Med. 1992; 92:513–522

    CAS  PubMed  Google Scholar 

  108. Venturini, I., Corsi, L., Avallone, R., Farina, F., Bedogni, G., Baraldi, C., Baraldi, M., Zeneroli, M.L.: Ammonia and endogenous benzodiazepine-like compounds in the pathogenesis of hepatic encephalopathy. Scand. J. Gastroenterol. 2001; 36: 423–425

    CrossRef  CAS  PubMed  Google Scholar 

  109. Victor, M., Adams, R.D., Cole, M.: The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration. Medicine (Baltimore) 1965; 44: 345–396

    CAS  PubMed  Google Scholar 

  110. Walker, C.O., Schenker, S.: Pathogenesis of hepatic encephalopathy with special reference to the role of ammonia. Amer. J. Clin. Nutr. 1970; 23: 619–632

    CAS  PubMed  Google Scholar 

  111. Watanabe, A., Shiota, T., Tsuji, T.: Cerebral edema during hepatic encephalopathy in fulminant hepatic failure. J. Med. 1992; 23: 29–38

    CAS  PubMed  Google Scholar 

  112. Wein, C., Koch, H., Popp, B., Oehler, G., Schauder, P.: Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 739–745

    CrossRef  PubMed  Google Scholar 

  113. Wong, F., Blendis, L.M.: Ascites and portal-systemic encephalopathy as complications of cirrhosis. Curr. Opin. Gastroenterol. 1993; 9: 391–396

    Google Scholar 

  114. Yonekura, T., Kamata, S., Wasa, M., Okada, A., Kawata, S., Tarui, S.: Simultaneous analysis of plasma phenethylamine, phenylethanolamine, tyramine and octopamine in patients with hepatic encephalopathy. Clin. Chim. Acta 1991; 199: 91–98

    CrossRef  CAS  PubMed  Google Scholar 

  115. Zieve, L.: The machanism of hepatic coma. Hepatology 1981; 1: 360–365

    CAS  PubMed  Google Scholar 

Therapy

  1. Bansky, G., Meier, P.J., Riederer, E., Walser, H., Ziegler, W.H., Schmid, M.: Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 1989; 97: 744–750

    CAS  PubMed  Google Scholar 

  2. Bianchi, G.P., Marchesini, G., Fabbri, A., Rondelli, A., Bugianesi, E., Zoli, M., Pisi, E.: Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J. Intern. Med. 1993; 233: 385–392

    CAS  PubMed  Google Scholar 

  3. Bosman, D.K., Buijs, van den, C.A.C.G., Haan, de, J.G., Maas, M.A.W., Chamuleau, R.A.F.M.: The effects of benzodiazepine-receptor antagonists and partial inverse agonists on acute hepatic encephalopathy in the rat. Gastroenterology 1991; 101: 772–781

    CAS  PubMed  Google Scholar 

  4. Cadranel, J.F., El Younsi, M., Pidoux, B., Zylberberg, P., Benhamou, Y., Valla, D., Opolon, P.: Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur. J. Gastroenterol. Hepatol. 1995; 7: 325–329

    CAS  PubMed  Google Scholar 

  5. Condon, R.E.: Effect of dietary protein on symptoms and survival in dogs with an Eck fistula. Amer. J. Surg. 1971; 121: 107–113

    CrossRef  CAS  PubMed  Google Scholar 

  6. Conn, H.O., Leevy, C.M., Vlahcevic, Z.R., Rodgers, J.B., Maddrey, W.C., Seef, L., Levy, L.L.: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573–583

    CAS  PubMed  Google Scholar 

  7. Del Rosario, M., Werlin, S.L., Lauer, S.J.: Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J. Clin. Gastroenterol. 1997; 25: 682–684

    PubMed  Google Scholar 

  8. Egberts, E.-H., Schomerus, H., Hamster, W., Jürgens, P.: Verzweigtkettige Aminosäuren bei der Behandlung der latenten portosystemischen Enzephalopathie. Eine placebo-kontrollierte Doppelblind-Cross-over-Studie. Z. Ernährungswiss. 1986; 25: 9–28

    CAS  PubMed  Google Scholar 

  9. Eriksson, L.S., Conn, H.O.: Branched-chain amino acids in the management of hepatic encephalopathy: an analysis of variants. Hepatology 1989; 10: 228–246

    CAS  PubMed  Google Scholar 

  10. Fenton, J.C.B., Knight, E.J., Humpherson, P.L.: Milk-and-cheese diet in portal-systemic encephalopathy. Lancet 1966/I: 164–166

    Google Scholar 

  11. Freund, H., Yoshimura, N., Fischer, J.E.: Chronic hepatic encephalopathy. Long-term therapy with a branched-chain amino-acid-enriched elemental diet. J. Amer. Med. Ass. 1979; 242: 347–349

    CAS  Google Scholar 

  12. Gebhardt, R., Beckers, G., Gaunitz, F., Haupt, W., Jonitza, D., Klein, S., Scheja, L.: Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J. Pharmacol. Exper. Ther. 1997; 283: 1–6

    CAS  Google Scholar 

  13. Greenberg, N.J., Carley, J., Schenker, St., Bettinger, I., Stamness, C., Beyer, P.: Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Dig. Dis. 1977; 22: 845–855

    Google Scholar 

  14. Grüngreiff, K., Kleine, F.-D., Musil, H.E., Diete, U., Franke, D., Klauck, S., Päge, I., Kleine, S., Lössner, B., Pfeiffer, K.P.: Valin und verzweigtkettige Aminosäuren in der Behandlung der hepatischen Enzephalopathie. Z. Gastroenterol. 1993; 31: 235–241

    PubMed  Google Scholar 

  15. Gyr, K., Meier, R., Häussler, J., Boulétreau, P., Fleig, W.E., Gatta, A., Holstege, A., Pomier-Layrargues, G., Schalm, S.W., Groneweg, M., Scollo-Lavizzari, G., Ventura, E., Zenerolli, M.L., Williams, R., Yoo, Y., Amrein, R.: Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double-blind, randomized, placebo-controlled multicentre study. Gut 1996; 39: 319–324

    CAS  PubMed  Google Scholar 

  16. Higuchi, K., Shimizu, Y., Nambu, S., Miyabayashi, C., Takahara, T., Saito, S., Hioki, O., Kuwabara, Y., Watanabe, A.: Effects of an infusion of branched-chain amino acids on neurophysiological and psychometric testings in cirrhotic patients with mild hepatic encephalopathy. J. Gastroenterol. Hepatol. 1994; 9: 366–372

    CAS  PubMed  Google Scholar 

  17. Horsmans, Y., Solbreux, P.M., Daenens, C., Desager, J.P., Geubel, A.P.: Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment. Pharmacol. Ther. 1997; 11: 165–170

    CrossRef  CAS  PubMed  Google Scholar 

  18. Horst, D., Grace, N.D., Conn, H.O., Schiff, E., Schenker, S., Viteri, A., Law, D., Atterbury, C.E.: Comparison of dietary protein with an oral branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 279–287

    CAS  PubMed  Google Scholar 

  19. Keohane, P.P., Attrill, H., Grimble, G., Spiller, R., Frost, P., Silk, D.B.A.: Enteral nutrition in malnourished patients with hepatic cirrhosis and acute encephalopathy. J. Parent. Ent. Nutr. 1983; 7: 346–349

    CAS  Google Scholar 

  20. Keshavarzian, A., Meek, J., Sutton, C., Emery, V.M., Hughes, E.A., Hodgson, H.J.F.: Dietary protein supplementation from vegetable sources in the management of chronic portal-systemic encephalopathy. Amer. J. Gastroenterol. 1984; 79: 945–949

    CAS  Google Scholar 

  21. Kircheis, G., Nilius, R., Held, C., Berndt, H., Buchner, M., Görtelmeyer, R., Hendricks, R., Krüger, B., Kuklinski, B., Meister, H., Otto, H.-J., Rink, C., Rösch, W., Stauch, S.: Therapeutic efficacy of L-ornithine-Laspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351–1360

    CrossRef  CAS  PubMed  Google Scholar 

  22. Laccetti, M., Manes, G., Uomo, G., Lioniello, M., Rabitti, P.G., Balzano, A.: Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. Dig. Liver Dis. 2000; 32: 335–338

    CrossRef  CAS  PubMed  Google Scholar 

  23. Liersch, J., Huth, K.: Beeinflussung der portosystemischen Enzephalopathie durch orale Zufuhr verzweigtkettiger Aminosäuren bei Patienten mit Leberzirrhose. Med. Welt 1985; 36: 448–454

    Google Scholar 

  24. Loguercio, C., Abbiati, R., Rinaldi, M., Romano, A., Del Vecchio Blanco, C., Coltori, M.: Long-term effects of Enterococcus faecium SF 68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy. J. Hepatol. 1995; 23: 39–46

    CrossRef  CAS  PubMed  Google Scholar 

  25. Marchesini, G., Dioguardi, F.S., Bianchi, G.P., Zoli, M., Bellati, G., Roffi, L., Martines, D., Abbiati, R.: Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. J. Hepatol. 1990; 11: 92–101

    CrossRef  CAS  PubMed  Google Scholar 

  26. Mas, A., Rodes, J., Sunyer, L., Rodrigo, L., Planas, R., Vargas, V., Castells, L., Rodriguez-Martinez, D., Fernandez-Rodriguez, C., Coll, I., Pardo, A.: Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, doubledummy, controlled clinical trial. J. Hepatol. 2003; 38: 51–58

    CrossRef  CAS  PubMed  Google Scholar 

  27. McClain, C.J., Potter, T.J., Kromhout, J.P., Zieve, L.: The effect of lactulose on psychomotor performance tests in alcoholic cirrhotics without overt hepatic encephalopathy. J. Clin. Gastroenterol. 1984; 6: 325–329

    CAS  PubMed  Google Scholar 

  28. Meier, P.J., Bansky, G.: Neue Möglichkeiten in der Therapie der hepatischen Enzephalopathie. Schweiz. Med. Wschr. 1990; 120: 553–556

    CAS  PubMed  Google Scholar 

  29. Mendenhall, C.L., Rouster, S., Marshall, L., Weesner, R.: A new therapy for portal systemic encephalopathy. Amer. J. Gastroenterol. 1986; 81: 540–543

    CAS  Google Scholar 

  30. Merli, M., Riggio, O., Pieche, U., Ariosto, F., Pinto, G., Romiti, A., Varriale, M., Capocaccia, L.: The effect of oral BCAA supplement on diurnal variations in plasma amino acid concentrations in cirrhotic patients. Nutrition 1988; 4: 351–356

    Google Scholar 

  31. Morgan, M.Y., Jakobovits, A.W., James, I.M., Sherlock, S.: Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 1980; 78: 663–670

    CAS  PubMed  Google Scholar 

  32. Morgan, M.H., Read, A.E., Speller, D.C.E.: Treatment of hepatic encephalopathy with metronidazol. Gut 1982; 23: 1–7

    CAS  PubMed  Google Scholar 

  33. Naylor, C.D., O’Rourke, K., Detsky, A.S., Baker, J.P.: Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989; 97: 1033–1042

    CAS  Google Scholar 

  34. Okita, M., Watanabe, A., Nagashima, H.: A branched-chain amino acid-supplemented diet in the treatment of liver cirrhosis. Curr. Therap. Res. 1984; 35: 83–92

    Google Scholar 

  35. Platell, C., Kong, S.-E., McCauley, R., Hall, J.C.: Branched-chain amino acids. J. Gastroenterol. Hepatol. 2000; 15: 706–717

    CrossRef  CAS  PubMed  Google Scholar 

  36. Plauth, M., Egberts, E.-H., Hamster, W., Török, M., Müller, P.H., Brand, O., Fürst, P., Dölle, W.: Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A doubleblind placebo-controlled crossover study. J. Hepatol. 1993; 17: 308–314

    CrossRef  CAS  PubMed  Google Scholar 

  37. Pomier-Layrargues, G., Gigue`re, J.F., Lavoie, J., Perney, P., Gagnon, S., Damour, M., Wells, J., Butterworth, R.F.: Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. Hepatology 1994; 19: 32–37

    CrossRef  CAS  PubMed  Google Scholar 

  38. Reding, P., Duchateau, J., Bataille, C.: Oral zinc supplementation improves hepatic encephalopathy. Lancet 1984/II: 493–494

    Google Scholar 

  39. Riggio, O., Balducci, G., Ariosto, F., Merli, M., Tremiterra, S., Ziparo, V., Capocaccia, L.: Lactitol in the treatment of chronic hepatic encephalopathy — a randomized cross-over comparison with lactulose. Hepato-Gastroenterol. 1990; 37: 524–527

    CAS  Google Scholar 

  40. Riggio, O., Merli, M., Capocaccia, L., Caschera, M., Zulio, A., Pinto, G., Gaudio, E., Franchitto, A., Stagnoli, R., D’Aquilino, E., Seri, S., Moretti, R., Cantafora, A.: Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology 1992; 16: 785–789

    CAS  PubMed  Google Scholar 

  41. Riordan, S.M., Williams, R.: Treatment of hepatic encephalopathy. New Engl. J. Med. 1997; 337: 473–479

    CrossRef  CAS  PubMed  Google Scholar 

  42. Rose, C., Michalak, A., Rama Rao, K.V., Quack, G., Kircheis, G., Butterworth, R.F.: L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30: 636–640

    CrossRef  CAS  PubMed  Google Scholar 

  43. Stauch, S., Kircheis, G., Adler, G., Becker, K., Ditschuneit, H., Görtelmeyer, R., Hendricks, R., Heuser, A., Karoff, C., Malfertheiner, P., Mayer, D., Rösch, W., Steffens, J.: Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J. Hepatol. 1998; 28: 856–864

    CrossRef  CAS  PubMed  Google Scholar 

  44. Sushma, S., Dasarathy, S., Tandon, R.K., Jain, S., Gupta, S., Bhist, M.S.: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trail. Hepatology 1992; 16: 138–144

    CAS  PubMed  Google Scholar 

  45. Tarao, K., Ikeda, T., Hayashi, K., Watanabe, A., Sakurai, A., Okeda, T., Ito, T., Karube, H., Nomoto, T., Mizuno, T., Shindo, K.: Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31: 702–706

    CAS  PubMed  Google Scholar 

  46. Tromm, A., Giga, T., Greving, I., Hilden, H., Hüppe, D., Schwegler, U., Micklefield, G.H., May, B.: Orthograde whole gut irrigation with mannite versus paromomycine plus lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000; 47: 473–477

    CAS  PubMed  Google Scholar 

  47. Uribe, M., Marquez, M.A., Ramos, G.G., Ramos-Uribe, M.H., Vargas, F., Villalobos, A., Ramos, C.: Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study. Dig. Dis. Sci. 1982; 27: 1109–1119

    CrossRef  CAS  PubMed  Google Scholar 

  48. Uribe; M., Garcia-Ramos, G., Ramos, M., Valverde, C., Marquez, M.A., Farca, A., Guevara, L.: Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Amer. J. Gastroenterol. 1983; 78: 517–522

    CAS  Google Scholar 

  49. Uribe-Esquivel, M., Moran, S., Poo, J.L., Munoz, R.M.: Invitro and invivo lactose and lactulose effects on colonic fermentation and portalsystemic encephalopathy parameters. Scand. J. Gastroenterol. 1997; 32(Suppl. 222): 49–52

    Google Scholar 

  50. Watanabe, A., Sakai, T., Sato, S., Imai, F., Ohto, M., Arakawa, Y., Toda, G., Kobayashi, K., Muto, Y., Tsujii, T., Kawasaki, H., Okita, K., Tanikawa, K., Fujiyama, S., Shimada, S.: Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410–1414

    CAS  PubMed  Google Scholar 

  51. Watanabe, A.: Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J. Gastroenterol. Hepatol. 2000; 15: 969–979

    CAS  PubMed  Google Scholar 

  52. Weber, F.L. jr.: Effects of lactulose on nitrogen metabolism. Scand. J. Gastroenterol. 1997; 32(Suppl. 222): 83–87

    CAS  Google Scholar 

  53. Williams, R., James, O.F.W., Warnes, T.W., Morgan, M.Y.: Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur. J. Gastroenterol. Hepatol. 2000; 12: 203–208

    CAS  PubMed  Google Scholar 

  54. Yang, S.S., Lai, Y.C., Chiang, T.R., Chen, D.F., Chen, D.S.: Role of zinc in subclinical hepatic encephalopathy: comparison with somatosencory-evoked potentials. J. Gastroenterol. Hepatol. 2004; 19: 375–379

    CrossRef  CAS  PubMed  Google Scholar 

  55. Yoshida, T., Muto, Y., Moriwaki, H., Yamato, M.: Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol. Japon. 1989; 24: 692–698

    CAS  Google Scholar 

  56. Zullo, A., Rinaldi, V., Hassan, C., Folino, S., Winn, S., Pinto, G., Attili, A.F.: Helicobacter pyloric and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Ital. J. Gastroenterol. Hepatol. 1998; 30: 405–409

    CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and Permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

(2006). Hepatic encephalopathy. In: Hepatology Principles and Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28977-1_15

Download citation

  • DOI: https://doi.org/10.1007/3-540-28977-1_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28976-0

  • Online ISBN: 978-3-540-28977-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

search

Navigation